Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Javier Queiruga‐Parada
Observed names:
J. Queiruga-Parada,
J. Queiruga‐Parada,
Javier Queiruga Parada,
Javier Queiruga-Parada,
Queiruga-Parada, J.
Institutions:
Hospital Universitario La Paz,
Hospital La Paz Institute for Health Research,
Spanish Clinical Research Network,
mAbxience Holding, S.L. (Spain)
Observed institutions:
Hospital Universitario La Paz,
Hospital La Paz Institute for Health Research,
Spanish Clinical Research Network,
mAbxience Holding, S.L. (Spain),
Universidad Autónoma de Madrid
ORCID:
0000-0001-6297-4167
Observed ORCID:
0000-0001-6297-4167
OpenAlex ID:
A5037201524
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
2021
·
François-Xavier Lescure
, Hitoshi Honda
, et al.
·
The Lancet Respiratory Medicine
·
274
PDF
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
2023
·
Júlia Corominas
, Carme Garriga
, et al.
·
The Lancet Regional Health - Europe
·
44
A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial
2020
·
Irene García García
, Miguel Rodriguez-Rubio
, et al.
·
Trials
·
43
PDF
Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)
2021
·
A. Pérez-Martínez
, M. Mora-Rillo
, et al.
·
EClinicalMedicine
·
37
PDF
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial
2022
·
Rocío Montejano
, Fernando de la Calle-Prieto
, et al.
·
Clinical Infectious Diseases
·
22
Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210)
2023
·
Cristina Ferreras
, Clara Hernández-Blanco
, et al.
·
Cytotherapy
·
18
Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial
2022
·
Irene García-García
, Enrique Seco-Meseguer
, et al.
·
Journal of Clinical Medicine
·
13
PDF
A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol
2021
·
I. García-García
, P. Guerra-García
, et al.
·
Trials
·
12
PDF
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial
2025
·
Júlia Corominas
, Carme Garriga
, et al.
·
Vaccine
·
7
Population PK Modeling of Denosumab Biosimilar MB09 and Reference Denosumab to Establish PK Similarity
2025
·
Sara Sánchez-Vidaurre
, Alexandra Paravisini
, et al.
·
Pharmaceutics
·
3
PDF
MB09 , a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects
2024
·
Monika Tomaszewska‐Kiecana
, Elisabete Carapuça
, et al.
·
Clinical and Translational Science
·
3
PDF
A randomized, double‐blind, single‐dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab
2023
·
C. Schwabe
, A. Cole
, et al.
·
Pharmacology Research & Perspectives
·
2
PDF
Immunotherapy: EVALUATION OF MEMORY T CELLS AS ADOPTIVE THERAPY IN CORONAVIRUS PNEUMONIA AND/OR LYMPHOPENIA: A PHASE II CLINICAL TRIAL (RELEASE NCT04578210)
2023
·
C. Ferreras
, C. Hernández
, et al.
·
Cytotherapy
·
1
PDF
A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia: (RELEASE NCT04578210)
2021
·
Antonio Pérez-Martínez
, Alejandro Martín-Quirós
, et al.
·
Blood
·
1
PDF
A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
2023
·
Antonio Perez-Martinez
, Cristina Ferreras
, et al.
·
Transplantation and Cellular Therapy
A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
2022
·
Antonio Perez
, Cristina Ferreras
, et al.
·
Blood
PDF
Monitoring SARS-CoV-2 aerosol transmission in hospitals
2021
·
Antonio Alcamı́
, Alberto Rastrojo Lastras
, et al.
·
Dialnet (Universidad de la Rioja)
Kounis syndrome secondary to heparin in a newborn with hypoplastic left heart.
2020
·
Paloma López Ortego
, Javier Queiruga Parada
, et al.
·
IBJ Clinical Pharmacology
Nuevos antibióticos en el tratamiento de la neumonía adquirida en la comunidad
2019
·
Javier Queiruga Parada
, Susana Almenara de Riquer
·
Actualidad en farmacología y terapéutica
Show more works
View as search
Works count:
23
Citation count:
480
H-index:
8
I10-index:
8
Year
Topic
Type